Precision medicine

The latest in the DDW eBook series ‘Immunotherapy: Where are the advances and breakthroughs?‘ is now available for download. This 24-page eBook sponsored by Sino Biological looks at the advances and breakthroughs taking place within immunotherapy. Download this exclusive eBook to learn more about: Advances in cancer care: Where are the advances in treatments for […]

This 24-page eBook sponsored by Sino Biological looks at the advances and breakthroughs taking place within immunotherapy. Download this exclusive eBook to learn more about: Advances in cancer care: Where are the advances in treatments for triple-negative breast cancer? Drug development: Five years of oncology developments Why immunotherapy is here to stay Precision cancer therapies: […]

HKG Epitherapeutics is a biotechnology company developing novel tools for the early detection of cancer and promoting healthy aging. Founder Dr Moshe Szyf Founder shares the potential of harnessing precision medicine.  Embarking on a new era of medicine  The advent of genomics has ushered in the era of personalised medicine, enabling us to analyse the […]

Eurofins Genomics has adopted Olink technology to advance proteomics research and accelerate its precision medicine programmes. The collaboration is designed to bolster the company’s offerings in the fields of research, population health, and regulated clinical trials. Olink Explore HT is the company’s latest solution for high-throughput proteomics, allowing scientists to accurately measure over 5,300 proteins […]

This is the latest episode of the free DDW narrated podcast, “What lies in the future for genomics and big data?”, which covers two articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “What’s the next step in big data and AI?” and “Why a recent advancement is a […]

A first in human study of a 3D printing drug product, T21, designed to treat moderate to severe ulcerative colitis (UC), has reported positive results. Imaging results from the study confirmed that T21 tablets are precisely delivered and released to the target site (the colon) for the drug release. The administration of oral medication is […]

An industry overview of the role of the microbiome in precision medicine, and its interplay with research tools, diagnostics, and therapeutic development. By Katie Gillette, Senior Project Leader, Eliza French, Analyst, and Graham Friedman, Analyst, DeciBio. The human microbiome refers to the vast array of microorganisms that live in and on the human body. With […]

Researchers will combine expertise in drug discovery, artificial intelligence (AI), and experimental cancer models and platforms in a new programme to design the precision cancer drugs of the future. Under an academic and commercial collaboration between The Institute of Cancer Research, London, the Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, and the company Vivan Therapeutics, a […]

By DDW Editor Reece Armstrong. If there’s one thing I would take from the Summer 2023 issue of Drug Discovery World, it would be that the application of technologies and processes throughout the pharmaceutical industry are changing how scientists pursue the development of therapies. Artificial intelligence (AI), gene editing, synthetic biology and more, are beginning […]

Cancer Research UK has joined the PRIME-ROSE project, a Europe-wide effort to boost patient access to precision cancer medicine (PCM). The PRIME-ROSE consortium consists of 24 partners, including nine beneficiaries and fifteen associated partners who will come together over the course of five years and work with regulators, policymakers, healthcare providers and patient advocacy groups […]

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this latest episode, DDW’s Megan Thomas is in conversation with Dr Pierre Eftehkari, Chief Sceitnific Officer of Inoviem Scientific. With more than 15 years of experience in drug development, […]

From antibody-drug conjugates and RNA, to CRISPR and CAR-T therapy, DDW asked the drug discovery industry what the most important development in oncology over the last five years has been. As the US National Cancer Research Month draws to a close, we asked experts from across the industry “What do you feel has been the […]

Not-for-profit medical research organisation LifeArc and techbio company PrecisionLife have agreed a strategic R&D collaboration to accelerate the discovery of targeted treatments for motor neurone disease (MND). MND is also known as amyotrophic lateral sclerosis (ALS) and Lou Gehrig’s disease. The collaboration will accelerate findings by PrecisionLife working with the Motor Neurone Disease Association and […]

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this latest episode, DDW’s Megan Thomas is in conversation with Dr Michael Pace, Global & Strategic Feasibility Expert at Rho.  Leveraging historical trial databases […]

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this latest episode, DDW’s Megan Thomas is in conversation with Dr Michael Pace, Global & Strategic Feasibility Expert at Rho.  Leveraging historical trial databases […]

AI drug discovery company MultiOmic Health has closed a £5 million ($6.2 million) seed funding extension round to build a precision therapeutics discovery platform for metabolic syndrome-related medical conditions. The round was led by London-based Hoxton Ventures, with participation from Ada Ventures, MMC Ventures and Verve Ventures. Since beginning operations in May 2021, MultiOmic has […]